Abstract: Background:Extended spectrum β-lactamase(ESBL) is an important mechanism of beta-
Introduction
Extended spectrum β-lactamase (ESBL) are β -lactamases capable of conferring bacterial resistance to the Penicillins, first, second, and third-generation cephalosporins, and Aztreonam (but not the Cephamycins or Carbapenems) by hydrolysis of these antibiotics, and which are inhibited by β-lactamase inhibitors such as clavulanic acid. [1] ESBLs belong to group 2be of Bush's functional classification. AmpCβ-lactamases belong to group I of Bush's functional classification and are susceptible to advanced spectrum cephalosporins(i.e. cefepime and cefpirome). [2] The ESBL confirmation method has been established by CLSI and is used worldwide. [3] This test however fails to detect ESBL in the presence of AmpC β lactamases (AmpC). [4] Several methods have been described for detection of ESBL in presence of AmpC but these may not be routinely used. The aim of the present study is to find the prevalence of ESBL producing E. coli causing urinary tract infections and to compare the two ESBL detection methods one given by CLSI using Ceftazidime-clavulanic acid and the other Cefepime-clavulanic acid .
II. Materials and Methods:
A total of 216 non repetitive E.coli isolates obtained from cultures of urine received between January 2012 to August 2012 were included in the study. Identification of these E. coli isolates was done using standard microbiological techniques. Antibiotic susceptibility testing was done according to CLSI recommended KirbyBauer disk diffusion method . [3] Each of these E.coli isolates were screened for possible ESBL production by using 30µg ofCefotaxime and 10 µg of Cefpodoxime disk. Every isolate that showed resistance to these screening agents was tested for ESBL detection by using (i)CLSI recommended method and (ii )cefepime-clavulanic acid method. The interpretation of results was as follows: 1.A ≥ 5mm increase in the zone diameter of the Ceftazidimealone and in combination with Clavulanicacid was indicative of ESBL production as per CLSI. 2. A ≥ 5mm increase in the zone diameter of the Cefepime alone and in combination with Clavulanic acid was indicative of ESBL production even in presence of AmpC . [5, 6, 7] E.coliATCC 25922 was taken as negative control and K. pneumoniaeATCC 700603 served as positive control.
III. Results and Discussion:
A total of 1136 urine samples were received in the laboratory during the study period out of which 216E.coli were isolated.These 216E.coli isolates were then screened for ESBL production by CLSI recommended screening method using 30µg of Cefotaxime and 10 µg of Cefpodoxime.Though, any third generation cephalosporin can be used, some workers have recommended Cefpodoxime disk as a good screening agent for ESBL detection in E. coli . [8] The number of potential ESBL producers identified by CLSI recommended screening test were 128 (59%). All screening test positive isolates were further tested for confirmation of ESBL production by CLSI recommended Phenotypic confirmatory test using Ceftazidime and Ceftazidime -Clavulanic acid and Disk Diffusion Method using Cefepime and Cefepime-Clavulanic acid.
Not all 128 screening test positive isolates were confirmed to be ESBL producers. Similarly other studies have also demonstrated that not all screen positive isolates were ESBL producers. [9, 10] Out of 128 screen test positive 109 (85.2%) isolates were positive by CLSI recommended method,112 (87.5%) were positive byCefepime-Clavulanic acidmethod. Thus 3 isolates of E.coli would have been missed by using only CLSI recommended method.As shown in Table 1 (A) and 1(B) .This difference was found to be statistically significant (p value<0.05,Chi square test, Graph Pad).
The ESBL isolates showed maximum sensitivity to Imipenem and Tigecycline followed by Nitrofurantoin as shown in Figure: 1.
In our study ESBL along with AmpC production accounted for 2.3% of E.coli isolates which were detected using Cefepime. Similar study from Chandigarh reported 2% of isolates having co-existence of Amp C and ESBLs. [11] A study from Haldwani reported as high as 25% of ESBL and Amp C co-production. [12] In conclusion, the results of the study indicate that the current CLSI recommended method to confirm ESBL enzymes by conducting clavulanate synergy tests with Ceftazidime may be insufficient for ESBL detection in clinical isolates of E.coli since this organism may produce multiple β-lactamases. In such situations, where AmpC β-lactamase can interfere with clavulanate synergy, Cefepime clavulanate could be a more sensitive alternative for the detection of ESBL producing organisms. This is consistent with other studies. [13] IV. 
